文献速递炎症性肠病

质子泵抑制剂对炎症性肠病英夫利西单抗疗效的影响:随机对照研究患者水平荟萃分析

The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies.
PubMed 文献 · Gut · 2020-12-17

该研究从Yale Open Data Access框架获取5项随机对照研究中接受英夫利西单抗治疗的成人中重度IBD患者个体数据,比较联用与未联用PPI者的结局。多因素分析和倾向评分匹配显示,PPI暴露与第30周缓解率显著降低相关(匹配后30% vs 49%,p<0.001),第54周结果类似,且住院率更高(15% vs 8%,p=0.007);克罗恩病亚组显著而UC未达显著。

要点

  • IBD患者联用PPI与英夫利西单抗第30周缓解率显著降低相关(OR 0.45,p<0.001)。
  • 倾向评分匹配后第30周缓解率PPI组30%、非PPI组49%(p<0.001)。
  • PPI组住院率更高(15% vs 8%,p=0.007),胃肠炎等不良事件无差异。

核心结论

  • 在接受英夫利西单抗治疗的IBD患者中,联用PPI者获得缓解的可能性更低。
  • 该结果提示需进一步研究PPI对IBD结局和治疗的影响。

研究设计与样本

  • 患者水平荟萃分析,数据来自Yale Open Data Access框架下5项随机对照研究。
  • 纳入接受英夫利西单抗治疗的成人中重度IBD患者,联用PPI者147例、未联用者889例。
  • 采用多因素分析和倾向评分匹配分析评估第30周缓解率、第54周缓解率和住院率。

主要发现

  • 多因素分析显示PPI组第30周缓解率显著更低(OR 0.45,p<0.001)。
  • 倾向评分匹配后第30周缓解率PPI组30%、非PPI组49%(p<0.001)。
  • 按疾病分层,克罗恩病中结果仍有统计学显著性,UC中未达显著性。
  • 第54周缓解率结果与第30周类似。
  • PPI组住院率更高(15% vs 8%,p=0.007);胃肠炎等不良事件率两组无差异。

关键数值与推荐

  • PPI组与非PPI组第30周缓解率分别为30%和49%(倾向评分匹配后,p<0.001)。
  • 多因素分析第30周缓解OR 0.45(p<0.001)。
  • 住院率PPI组15%、非PPI组8%(p=0.007)。

临床怎么用

  • 对接受英夫利西单抗治疗的IBD患者,应关注联用PPI可能带来的缓解率下降和住院风险。
  • 克罗恩病患者联用PPI时尤其需评估继续使用的必要性。

局限性

  • PPI组患者年龄更大、白人比例更高、使用免疫调节剂治疗的比例更低。
  • UC亚组中未达到统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In treating patients with inflammatory bowel disease (IBD), how concomitant medications influence the response to infliximab is largely unexplored. We aim to evaluate whether proton pump inhibitors (PPIs) affect the response to infliximab therapy in patients with IBD. DESIGN: Patient-level data of adult patients with moderate-to-severe IBD treated with infliximab were obtained from the Yale Open Data Access Framework. Multivariable analysis and propensity score-matched analysis were performed to assess week 30 remission rates, week 54 remission rates and hospitalisation rates in patients on infliximab therapy with and without PPI exposure. RESULTS: Among the five randomised controlled studies, there were 147 and 889 patients on infliximab with and without PPI therapy, respectively. Patients on PPI were older, more likely to be Caucasian and were less likely to be on immunomodulator therapy. Patients on PPI were significantly less likely to achieve week 30 remission on multivariable analysis (OR 0.45, p<0.001). Following propensity score matching adjusting for baseline difference in patient characteristics, the week 30 remission rates were 30% and 49% in patients with and without PPI therapy, respectively (p<0.001). Analysing separately for disease, the findings remained statistically significant in Crohn's disease but did not reach significance in UC. Similar results were seen with week 54 remission rates. Patients on PPI were also more likely to be hospitalised (15% vs 8%, p=0.007). Rates of adverse events such as gastroenteritis were not different between the two groups. CONCLUSION: In this patient-level meta-analysis of randomised controlled studies, we found that patients with IBD taking PPI were less likely to achieve remission while on infliximab therapy. The results of our study warrant further investigation into the effect of PPI on IBD outcomes and therapies.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Lu TX, Dapas M, Lin E, et al. The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies. Gut. 2020. PMID: 33334900. doi:10.1136/gutjnl-2020-321609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。